Neurizon Therapeutics (FRA:ECQ0) Accounts Payable: €3.01 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Neurizon Therapeutics Accounts Payable?

Neurizon Therapeutics FRA:ECQ0 Accounts Payable is €3.01 Mil as of Dec. 2025. The stock has 2 warning signs investors should review.

Neurizon Therapeutics's Accounts Payable for the quarter that ended in Dec. 2025 was €3.01 Mil.

Neurizon Therapeutics's quarterly Accounts Payable declined from Dec. 2024 (€2.14 Mil) to Jun. 2025 (€0.72 Mil) but then increased from Jun. 2025 (€0.72 Mil) to Dec. 2025 (€3.01 Mil).

Neurizon Therapeutics's annual Accounts Payable declined from Jun. 2023 (€0.57 Mil) to Jun. 2024 (€0.51 Mil) but then increased from Jun. 2024 (€0.51 Mil) to Jun. 2025 (€0.72 Mil).

Neurizon Therapeutics Accounts Payable Related Terms

Neurizon Therapeutics Accounts Payable Historical Data

* Premium members only.

The historical data trend for Neurizon Therapeutics's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neurizon Therapeutics Accounts Payable Chart

Neurizon Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.36 0.40 0.57 0.51 0.72

Neurizon Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.67 0.51 2.14 0.72 3.01

Neurizon Therapeutics Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of €3.01 Mil mean?
Neurizon Therapeutics (FRA:ECQ0) has a Accounts Payable of €3.01 Mil as of Dec. 2025. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Neurizon Therapeutics and its competitors.
Is Neurizon Therapeutics' Accounts Payable too high?
Neurizon Therapeutics' current Accounts Payable is €3.01 Mil.
How does Neurizon Therapeutics' Accounts Payable compare to VRTX and REGN?
Neurizon Therapeutics' Accounts Payable of €3.01 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Neurizon Therapeutics and its competitors. Neurizon Therapeutics's current Accounts Payable is €3.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurizon Therapeutics stock overvalued right now?
Neurizon Therapeutics (FRA:ECQ0) has a current Accounts Payable of €3.01 Mil. The current Accounts Payable is €3.01 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Neurizon Therapeutics (FRA:ECQ0), the current Accounts Payable is €3.01 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Neurizon Therapeutics Business Description

Other Exchanges ECQ0:GermanyNUZ:Australia
Address 385 Bourke Street, Suite 2, Level 11, Melbourne, VIC, AUS, 3205
Neurizon Therapeutics Ltd is a clinical-stage biotech company that develops drug discovery intellectual property for the treatment of different types of neurodegenerative diseases. Its product pipeline is NUZ-001 (S-Monepantel).